Terricabras Emma, Benjamim Claudia, Godessart Nuria
Department of Biology, Almirall Research Center, Cardener 68-74, 08024 Barcelona, Spain.
Autoimmun Rev. 2004 Nov;3(7-8):550-6. doi: 10.1016/j.autrev.2004.07.037.
The blockade of leukocyte migration has been demonstrated to be a valid option for the treatment of several autoimmune diseases. Chemokines play an active role in regulating cell infiltration into inflammatory sites and disrupting chemokine-receptor interactions has emerged as an alternative therapeutic approach. Pharmaceutical companies have developed an intense activity in the drug discovery of chemokine receptor antagonists in the last 10 years. Potent and selective compounds have been obtained and some of them are currently being evaluated in the clinic. The success of these trials will demonstrate whether the blockade of a single receptor is of therapeutic benefit. Alternative approaches, such as pan-receptor antagonists or inhibitors of the signalling pathways evoked by chemokines, are also being explored. In the meantime, new relationships between chemokines and receptors will be revealed, increasing our knowledge of such a fascinating field.
白细胞迁移的阻断已被证明是治疗多种自身免疫性疾病的有效选择。趋化因子在调节细胞浸润到炎症部位中发挥着积极作用，而破坏趋化因子-受体相互作用已成为一种替代治疗方法。在过去10年里，制药公司在趋化因子受体拮抗剂的药物研发方面开展了大量活动。已经获得了强效且选择性的化合物，其中一些目前正在临床评估中。这些试验的成功将证明阻断单一受体是否具有治疗益处。同时，也在探索其他方法，如泛受体拮抗剂或趋化因子引发的信号通路抑制剂。与此同时，趋化因子与受体之间的新关系将被揭示，增加我们对这一迷人领域的了解。
